Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg Conference

DEVON, Pa., April 05, 2023 -- Zynerba Pharmaceuticals, Inc. , the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today... | April 5, 2023

Related Keywords

Peter Vozzo ,Zynerba Pharmaceuticals Inc ,Exchange Commission ,European Medicines Agency ,Nasdaq ,Westin Crown Center ,Drug Administration ,European Commission ,Zynerba Pharmaceuticals ,Gatlinburg Conference ,Kansas City ,Sustained Efficacy ,Transdermal Gel ,Fragilex Syndrome ,Crown Center ,Efficacy Study ,Fast Track ,Private Securities Litigation Reform Act ,Nc Stock Exchange ,News ,Information ,Press Release ,Pril ,023 ,Zynerba ,The ,Leader ,N ,Nnovative ,Transdermal ,Cannabinoid ,Therapies ,Or ,Orphan ,Europsychiatric Zyne Us98986x1090 ,